Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for ORINF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
March 31, 2026 21.64%
December 31, 2025 37.47%
September 30, 2025 22.71%
June 30, 2025 19.79%
March 31, 2025 17.26%
December 31, 2024 16.90%
September 30, 2024 34.09%
June 30, 2024 15.87%
March 31, 2024 14.19%
December 31, 2023 23.39%
September 30, 2023 20.38%
June 30, 2023 12.59%
March 31, 2023 15.64%
December 31, 2022 10.76%
September 30, 2022 39.55%
June 30, 2022 23.30%
March 31, 2022 21.18%
December 31, 2021 11.86%
September 30, 2021 18.85%
June 30, 2021 21.97%
March 31, 2021 22.18%
December 31, 2020 9.98%
September 30, 2020 20.54%
June 30, 2020 25.85%
March 31, 2020 24.08%
Date Value
December 31, 2019 16.47%
September 30, 2019 25.24%
June 30, 2019 16.21%
March 31, 2019 17.76%
December 31, 2018 20.46%
September 30, 2018 15.46%
June 30, 2018 22.59%
March 31, 2018 21.72%
December 31, 2017 20.46%
September 30, 2017 17.64%
June 30, 2017 21.21%
March 31, 2017 25.16%
December 31, 2016 17.01%
September 30, 2016 28.04%
June 30, 2016 24.06%
March 31, 2016 24.16%
December 31, 2015 15.06%
September 30, 2015 18.95%
June 30, 2015 22.63%
March 31, 2015 25.28%
December 31, 2014 15.98%
September 30, 2014 20.90%
June 30, 2014 24.58%
March 31, 2014 21.47%
December 31, 2013 20.43%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 20.15%
ANI Pharmaceuticals, Inc. 11.55%
Corcept Therapeutics, Inc. -18.92%
Assertio Holdings, Inc. -189.8%
Veru, Inc. --